CSIMarket
 
Cincor Pharma Inc   (CINC)
Other Ticker:  
 
 
Price: $29.0600 $-0.14 -0.479%
Day's High: $29.35 Week Perf: -1.09 %
Day's Low: $ 29.02 30 Day Perf: 1.11 %
Volume (M): 6,350 52 Wk High: $ 0.00
Volume (M$): $ 184,522 52 Wk Avg: $0.00
Open: $29.17 52 Wk Low: $0.00



 Market Capitalization (Millions $) 1,186
 Shares Outstanding (Millions) 41
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) 111
 Capital Exp. (TTM) (Millions $) 0

Cincor Pharma Inc
Cincor Pharma Inc.


   Company Address: 230 Third Avenue, Waltham 2451 MA
   Company Phone Number: 531-1834   Stock Exchange / Ticker: NASDAQ CINC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Monopar Therapeutics Inc

Between many corporations, the MNPR issued as well the fourth quarter of 2023 numbers

Investors in the stock market have something to celebrate as the October to December 31, 2023 reporting cycle resumes. Numerous corporations, including those in the Major Pharmaceutical Preparations industry, have announced their earnings, and one company that stands out is Monopar Therapeutics Inc. (Nasdaq: MNPR).
Despite facing some challenges, Monopar Therapeutics has shown resilience and determination in its day-to-day operations, resulting in a significant improvement in its financial performance compared to the previous year. In the fourth quarter of 2023, the company reported an operating shortfall of $-1.911988 million, which is a clear improvement over the $-2.896 million reported in the same period of 2022.

Casi Pharmaceuticals Inc

Looking into fourth quarter of 2023 numbers, the Major Pharmaceutical Preparations company's saw a stunning -21.407 %, in revenue

Declining business caused an increase in deficit for the fiscal three months ending December 31 2023, Casi Pharmaceuticals Inc s' deficit per share inched up to $-2.02 from $-3.01 where Revenue went down by -21.407 % to $33.88 million from $43.11 million a year ago.

Neurobo Pharmaceuticals Inc

Neurobo Pharmaceuticals Inc Surprises Investors with Strong Fiscal Fourth Quarter Earnings

he midst of a challenging October to December 2023 reporting season, Neurobo Pharmaceuticals Inc (NRBO) has managed to deliver some encouraging news to investors. Despite expectations of no adjustments at the top-line, the company's operating loss for this period amounted to $-5.667 million. While this figure might raise concerns under different circumstances, it signifies a significant improvement compared to the corresponding period the previous year, which reported an operating loss of $-10.43 million.
This positive development at Neurobo Pharmaceuticals Inc, a major player in the field of Pharmaceutical Preparations, has instilled confidence in market observers. The company's ability to reduce its deficit per share from $-43.44 in the preceding fiscal year to $-2.46, represents a remarkable turnaround. Additionally, Neurobo Pharmaceuticals Inc recorded revenue of $0.00 million for the fiscal 12 Months 2023, a small indication of their ongoing efforts towards establishing prosperous revenue streams.

Agile Therapeutics Inc

Agile Therapeutics Inc. Faces Financial Struggles Amidst Declining Sales Performance

Agile Therapeutics Inc. is a major pharmaceutical preparations company that has recently reported a shortfall in its financial results for the fiscal span of October to December 31, 2023. The company posted a per-stock shortfall of $-1.49 per share, compared to $0.44 per share in the previous year, indicating a significant decline. Additionally, this shortfall represents a decline from the prior financial reporting period, where the per-share shortfall was $-0.27.
Another concerning aspect of Agile Therapeutics Inc.'s financial performance is the substantial decrease in revenue. The company's revenue receded by -14.368% to $3.42 million from $4.00 million in the comparable financial reporting period a year prior. Furthermore, the revenue also tumbled by -44.689% sequentially from $6.19 million. These figures point to a significant decline in the company's financial health.

Tenax Therapeutics Inc

Among many companies, the TENX published also the fourth quarter of 2023 performance

The shareholders have not expected some adjustments at the top-line during the the earnings cycle of fiscal October to December 31 2023 at the Tenax Therapeutics Inc . Yet, they observe the Major Pharmaceutical Preparations company's operating surplus that came in at $3.340937 million, during the matching time.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com